Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
Centene Corporation, a Fortune 100 company, is a diversified, multi-national healt...
Centene Corporation, a Fortune 100 company, is ...
Genetic Technologies is a leader in the development of genetic technology. Our tes...
Genetic Technologies is a leader in the develop...
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States a...
DLH (NASDAQ:DLHC) serves federal government cli...
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and d...
Cocrystal Pharma, Inc. is a clinical stage biot...
Radius is a science-driven fully integrated biopharmaceutical company that is comm...
Radius is a science-driven fully integrated bio...
Join the National Investor Network and get the latest information with your interests in mind.